Participants were randomized to double-blind treatment with low-dose oral 17-estradiol ( 0.5 mg/d ) ( n = 97 ) , low-dose venlafaxine hydrochloride extended release ( 75 mg/d ) ( n = 96 ) , or placebo ( n = 146 ) for 8 weeks .